Anamnestic response after antigen re-exposure following Ebola vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo in a phase I study

Архивировано 04.10.2021: escmid-2019-P0398.pdf

Источник: Goldstein N., et al. Anamnestic response after antigen re-exposure following Ebola vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo in a phase I study. ESCMID, 2019, P0338

The Ad26, MVA (0, 56) vaccine regimen was well tolerated in adults in a country previously affected by Ebola. Robust and persistent immune responses to the vaccine regimen were observed. Ad26, MVA vaccine regimens may be suitable for vaccination strategies in countries susceptible to Ebola outbreaks.